A new guidance document by the federal government is supposed to help speed the process by which drugs make the journey from the laboratory into clinical practice, but elements of the guidelines are raising some concerns about the safety of human subjects.
At a press conference on January 12, the US Food and Drug Administration (FDA) released documents covering exploratory investigational new drug (IND) studies that appear to relax some of the documentation requirements and safety parameters surrounding the early-stage testing of potential new drugs. The FDA said it is simply alerting pharmaceutical manufacturers and researchers to the level of due diligence required to satisfy government regulations that has been in effect all along.
Mitka M. Guidelines Aim to Speed Drug Approval While Protecting Human Subjects. JAMA. 2006;295(9):988–989. doi:10.1001/jama.295.9.988
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: